Purpose: Assessement of overal survival and disease - free survival after treatment of surgery and chemotherapy combination with osteosarcoma and analysis some survival-related factors. Patiens and methods
A restrospective and prospective describle study on 95 eligible patients with stade II osteosarcoma in long bones are treated with extremities, or limbs conservation surgery combinated with chemotherapy regimen consisting of Doxorubicin and Cisplatin in K hospital from 6/2000 to 9/2007. Results: The Overal 3 year- survival rate is 69,6 percent, Overal 5 year- survival rate is 62,6 percent, The Event-free 3 year- survival rate is 58,1 percent, Event-free 5 yearsurvival rate is 58,1 percent.The variable analysis: the overal and Event-free survival at 5 years are different between the following groups depending on: the invasive solt tissue of tumour: group :5 4 cm is 74,7 percent and 73,7 percent
group 4 cm is 48 percent and 43,6 percent (Logrank p 0,05), the overal and Event-free survival at 3 years are different between the following groups depending on the preoperative alkalization phosphatase, that means in the group serum alkalization phosphatase concentration less than 279 U/I there are 94,7 percent and 94,1 percent
from 279 U/I to 558 U/I there are 90,4 percent and 89,5 percent
goup 558 U/I there are 33,7 percent and 29,9 percent Logrank, p0,05. The relationship between Overal 3 year- survival and metastasis date after treatment 12 months is 34,7 percent, 12 months is 0 percent, Logrank p 0,05. The multivariable analysis gave some bad factors, that are independent prognostic on survival rates: position of femur, 85 percent chemotherapy dose, twice higher concentration befor-surgery than normal of serum alkalization phosphatase and metastasis after treatment. Conclusion: Surgery combination with chemotherapy have significantly improved survival time for patients with osteosarcoma.